Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

74P - The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients (pts) with locally recurrent or metastatic triple negative breast cancer (TNBC): a multi-cohort, phase II trial

Date

08 Dec 2022

Session

Poster Display

Presenters

Linda Liu

Citation

Annals of Oncology (2022) 16 (suppl_1): 100102-100102. 10.1016/iotech/iotech100102

Authors

L. Liu, X. Jin, Y. Xu, S. Wu, Y. Yang, L. Chen, W. Zhang, L. Ma, X. Hu, Z. Wang, Y. Jiang, Z. Shao

Author affiliations

  • Fudan University Shanghai Cancer Center, Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 74P

Background

This is a multi-cohort, phase II trial to evaluate the safety and preliminary antitumor activity of 70 mg (cohort A) or 100 mg (cohort B) sitravatinib QD plus tislelizumab in pts with locally recurrent or metastatic TNBC, and their combination with nab-paclitaxel in untreated locally recurrent inoperable or metastatic TNBC pts (cohort C). The preliminary result of cohort A has been reported with ORR of 38.1% (Lei Fan. JCO 2022 40:16_suppl). This analysis aims to report the updated analysis in cohort A and the interim results in cohort B.

Methods

Pts with locally recurrent or metastatic TNBC were included and received 70 mg (cohort A) or 100 mg (cohort B) sitravatinib QD PO and 200 mg tislelizumab IV Q3W until disease progression or intolerable toxicity. The primary endpoints included ORR (cohort A and B) and rate of grade ≥3 treatment-related adverse events (TRAEs) (cohort B). Secondary endpoints included DCR, PFS, and safety/tolerability. Updated analysis was provided for cohort A (Simon's 2 stage design). A Bayesian optimal phase II design with one interim analysis (on the first 20 pts out of the total 40 efficacy evaluable pts) was employed for cohort B to monitor both efficacy and safety primary endpoints simultaneously. The stopping boundary of interim analysis was the number of pts with ORR ≤1 or with grade ≥3 TRAEs ≥13.

Results

The data cutoff date of this analysis is 29 July 2022. In cohort A, with the median follow up of 10.7 months, the median PFS was 9.7 (95% CI: 2.8, 12.5) months among 21 efficacy evaluable pts. The rate of grade ≥3 TRAEs was 33.3% (7/21). In cohort B, among the first 20 efficacy evaluable pts with the median follow up of 4.1 months, 9 (45.0% [95% CI: 23.8%-67.9%]) pts were with confirmed ORR and 4 (20%) pts experienced grade ≥3 TRAEs, which met the interim goal. DCR was 80.0% (95% CI: 56.3%-94.27%). At the data cutoff, cohort B achieved the predefined enrollment target.

Conclusions

Sitravatinib combined with tislelizumab demonstrated clinically meaningful anti-tumor activity and had a manageable safety profile in the targeted pts population.

Clinical trial identification

NCT04734262.

Legal entity responsible for the study

The authors.

Funding

BeiGene (Beijing) Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.